InVivoMAb anti-mouse osteopontin (SPP1)
Product Details
The 100D3 monoclonal antibody reacts with mouse osteopontin (OPN), also known as SPP1. Osteopontin is a secreted arginine-glycine-aspartic acid (RGD)-containing glycoprotein that was originally isolated from bone. Osteopontin has been found in kidney, vascular tissues, biological fluids, and various tumor tissues. Osteopontin interacts with integrins and CD44 and regulates diverse biological processes including bone development, immune responses, and oncogenesis. Osteopontin is elevated in human colorectal cancer and is thought to function as an immune checkpoint. The 100D3 antibody is a blocking antibody that has been shown to increase the efficacy of tumor-specific CTLs in killing colon tumor cells in vitro and suppress colon tumor growth in tumor-bearing mice in vivo.Specifications
| Isotype | Mouse IgG2c, Īŗ |
|---|---|
| Recommended Isotype Control(s) | InVivoMAb mouse IgG2c isotype control, anti-dengue virus |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Conjugation | This product is unconjugated. Conjugation is available via our Antibody Conjugation Services. |
| Immunogen | Recombinant mouse OPN protein |
| Reported Applications |
in vivo OPN neutralization in vitro OPN neutralization ELISA |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
<2EU/mg (<0.002EU/Ī¼g) Determined by LAL gel clotting assay |
| Purity |
>95% Determined by SDS-PAGE |
| Sterility | 0.2 Ī¼M filtered |
| Purification | Protein A |
| RRID | AB_2927509 |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |
Recommended Products
-
Recommended Isotype Control(s)
InVivoMAb mouse IgG2c isotype control, anti-dengue virus
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer
in vivo OPN neutralization, in vitro OPN neutralization, ELISA
Klement, J. D., et al. (2021). "Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression" Cancers (Basel) 13(5). PubMed
Human colorectal cancers are mostly microsatellite-stable with no response to anti-PD-1 blockade immunotherapy, necessitating the development of a new immunotherapy. Osteopontin (OPN) is elevated in human colorectal cancer and may function as an immune checkpoint. We aimed at elucidating the mechanism of action of OPN and determining the efficacy of OPN blockade immunotherapy in suppression of colon cancer. We report here that OPN is primarily expressed in tumor cells, myeloid cells, and innate lymphoid cells in human colorectal carcinoma. Spp1 knock out mice exhibit a high incidence and fast growth rate of carcinogen-induced tumors. Knocking out Spp1 in colon tumor cells increased tumor-specific CTL cytotoxicity in vitro and resulted in decreased tumor growth in vivo. The OPN protein level is elevated in the peripheral blood of tumor-bearing mice. We developed four OPN neutralization monoclonal antibodies based on their efficacy in blocking OPN inhibition of T cell activation. OPN clones 100D3 and 103D6 increased the efficacy of tumor-specific CTLs in killing colon tumor cells in vitro and suppressed colon tumor growth in tumor-bearing mice in vivo. Our data indicate that OPN blockade immunotherapy with 100D3 and 103D6 has great potential to be further developed for colorectal cancer immunotherapy and for rendering a colorectal cancer response to anti-PD-1 immunotherapy.
